|
Product name
|
RUXOLITINIB PHOSPHATE
|
|
CAS No.
|
1092939-17-7
|
|
EINECS
|
/
|
|
Formula
|
C17H21N6O4P
|
|
Molecular Weight
|
404.37
|
|
Appearance
|
White to Off-White Solid
|
|
Purity
|
≥98%
|
|
Type
|
Pharmaceutical Intermediates
|
- Targeted JAK inhibitors: Ruxolitinib phosphate is a selective inhibitor of Janus kinase (JAK) 1 and JAK2, specifically used to treat various hematological diseases, including myelofibrosis and polycythemia vera .
- CLINICAL PROVEN EFFICACY: This compound has been clinically proven to significantly reduce symptoms associated with myelofibrosis, such as splenomegaly and debilitating systemic symptoms.
- Integrated Manufacturing: As an integrated production and trading factory, we ensure consistent quality and reliable supply of Ruxolitinib Phosphate.
- Compliant with regulations: Produced in accordance with international pharmaceutical standards to ensure safety and effectiveness.
- Expertise and Innovation: Our advanced facilities and experienced team enable us to provide high-quality pharmaceutical products customized as per market needs.
